Monitoring Brain Activity in Human Brain Injury
|ClinicalTrials.gov Identifier: NCT00258505|
Recruitment Status : Unknown
Verified October 2005 by Soroka University Medical Center.
Recruitment status was: Not yet recruiting
First Posted : November 24, 2005
Last Update Posted : August 1, 2007
|Condition or disease||Intervention/treatment|
|Traumatic Brain Injury Aneurysmal Subarachnoid Hemorrhage Cerebral Infarction Cerebral Hemorrhage||Procedure: Procedure: intracranial monitoring up to 9 days after injury|
Cortical spreading depression (CSD) is a wave of mass neuronal firing and neuronal and glial depolarisation which propagates through grey matter in the central nervous system in response to a pathologic stimulus, at a rate of between 1 and 5 mm per minute. First described by Leão in 1944 as a sudden depression of ECoG amplitude spreading across the cortex of the rabbit (Leao, A. A. P. 1944), CSD can be elicited in experimental animals by chemical, electrical, and mechanical stimuli, with varying degrees of ease. CSD provoked in healthy, normally perfused neural tissue does not induce persistent metabolic stress or cellular damage, and indeed such induction of CSD in animal experiments may confer protection against the adverse effects of a subsequent ischaemic insult (Kobayashi, S. et al. 1995).
In animal models of focal cerebral ischaemia, usually induced by occlusion of the middle cerebral artery, a spontaneous phenomenon occurs around the periphery of the core territory, with electrophysiological features essentially identical with CSD, and similar capacity to propagate across cerebral cortex. Designated "peri-infarct depolarisation" (PID), this event is associated with infarct expansion, or recruitment of at-risk cortical territory into the expanding core, and has been shown capable of causing this expansion, in the absence of therapeutic intervention. Indeed it has been hypothesized that glutamate release may be involved in PID generation, and that excitotoxicity may accomplish detrimental effects via this route (Hossmann, K. A. 1994), (Obrenovitch, T. P. and Urenjak, J. 1997). Some experimental neuroprotection treatments for stroke act to decrease the incidence of PID (Iijima, T. et al. 1992;Chen, Q. et al. 1993;Busch, E. et al. 1996).
In traumatic and ischaemic (especially in middle cerebral artery occlusion and aneurysmal subarachnoid haemorrhage) brain injury in humans, a phase of delayed deterioration often associated with severe and refractory brain swelling develops between 2 and 5 days after the initial ictus, and is associated with poor or fatal outcome. The cause and mechanism of this deterioration remain poorly understood, and the possibility exists that CSD/PID events might contribute to deterioration.
To date, CSD or PID have been reported in only ten human subjects in two papers (Mayevsky, A. et al. 1996; Strong, A. J. et al. 2002). Strong et al. reported that transient ECoG suppressions suggestive of depolarisations are common - but by no means universal - after brain injury in humans. Sub-dural ECoG electrode strips were placed in 14 patients who had undergone craniotomy for trauma or intracranial hemorrhage; monitoring was for up to 60 h following the injury. Five of these patients (36%) showed patterns of ECoG depression consistent with PID/CSD in brain regions adjacent to the primary injury.
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Observational Model:||Defined Population|
|Observational Model:||Natural History|
|Official Title:||Incidence, Nature and Consequences of Cortical Depolarizations in Human Brain Injury From Trauma and Ischemia: The COSBID Study|
|Study Completion Date :||September 2007|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00258505
|Contact: Anthony Strong, Prof.||Anthony.firstname.lastname@example.org|
|Contact: Jens Dreier, MD email@example.com|
|Principal Investigator: Jens Dreier, MD|
|Soroka||Not yet recruiting|
|Beer-Sheva, Israel, 84101|
|Contact: Alon Friedman, MD/PhD firstname.lastname@example.org|
|Principal Investigator: Alon Friedman, MD/PhD|
|Principal Investigator:||Alon Friedman, MD/PhD||Soroka University Medical Center|
|Principal Investigator:||Jens Dreier, MD||Charite, Berlin, Germany|